Phase 1/2a LYM1002 study of ibrutinib (ibr) plus nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder statusBrendan Hodkinson,Michael Schaffer,Joshua Brody,Wojciech Jurczak,Cecilia Carpio,Dina Ben-Yehuda,Irit Avivi,Rao Saleem,Muhit Ozcan,John Alvarez,Rob Ceulemans,Nele Fourneau,Sriram Balasubramanian,Anas YounesCANCER RESEARCH（2019）引用 0|浏览35暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
